Intercept Pharmaceuticals Stock Overreacts To Company Communiqué, Presents Buy Opportunity

  • Intercept Pharmaceuticals saw yet another slump in its price.
  • The company plans to boost revenue by capturing international markets.
  • The company plans to boost revenue by capturing international markets.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) stock suffered another setback as the company posted a letter it had sent to doctors about its Ocaliva product. The letter detailed out some rather stark adverse impact of overdosing on Ocaliva. As a result, the stock tanked more than 14 percent in a single day.

The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.

An abridged version is available below to our investor members. Login or Subscribe here.


$TSRO At Attractive Valuation Ahead Of Key Regulatory Decisions $ACAD – Where’s The Upside From Current Levels?